W

hen you think of CRISPR, the suffix “Cas9” seems immediately to spring to mind. But the Cas9 enzyme isn’t the only endonuclease that could be used therapeutically, according to North Carolina-based Locus Biosciences.

The startup is exploring the use of CRISPR/Cas3 in developing a new line of drugs that kill bacteria and fungi. If Cas9 works like scissors in gene editing, Cas3 is like Pac-Man — it just eats away at DNA. And it looks like it’s got its own unique set of applications. STAT chatted with Locus CEO Paul Garofolo, as well as cofounder Rodolphe Barrangou, who discovered this technology:

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.